Key result
Severe kidney impairment linked to ~5-fold higher tiapride exposure, requiring substantial dose reduction.
Why the study?
Kidney impairment is common in the elderly and may influence tiapride pharmacokinetics, but pharmacokinetic alterations of tiapride in patients with kidney disease have not been described.
How does renal impairment affect the pharmacokinetics of tiapride in elderly patients?
Observational (n=71)
How does renal impairment affect the pharmacokinetics of tiapride in elderly patients?
Renal function is the key determinant of tiapride pharmacokinetics, requiring substantial dose reduction in severe kidney impairment to prevent overdose.
Answers are grounded in this paper and cite their sources.
May warrant renal-based tiapride dosing in elderly patients; leaves open need for prospective safety and efficacy trials.
BACKGROUND: Tiapride is widely used for the treatment of confusion in the elderly and for other indications. Kidney impairment is common in the elderly population and may influence tiapride pharmacokinetics. However, pharmacokinetic alterations of tiapride in patients with kidney disease have not been described so far. METHODS: We studied tiapride pharmacokinetics in 71 predominantly elderly patients with various degrees of kidney impairment, including patients receiving hemodialysis. A population pharmacokinetic model and Monte Carlo simulations were used to evaluate tiapride exposure and optimize dosing across different degrees of renal impairment. RESULTS: Tiapride pharmacokinetics was strongly dependent on renal function, while other tested covariates had no significant effect. Drug exposure was approximately fivefold higher in patients with severe kidney impairment, indicating the need for substantial dose reduction to prevent overdose. The model enabled development of dosing recommendations for patients with CKD, including those receiving hemodialysis. Due to prolonged elimination in advanced CKD, drug effects may persist for several days after discontinuation. CONCLUSION: Renal function is the key determinant of tiapride pharmacokinetics. These findings provide practical dosing recommendations for elderly patients with kidney impairment and may improve the safety of tiapride therapy in clinical practice.
No takes yet. Share an insight, caveat, or question.
Halouzková et al. (2026) conducted an observational in Kidney impairment (n=71). Tiapride was evaluated on Tiapride pharmacokinetics and drug exposure. Tiapride exposure was approximately fivefold higher in patients with severe kidney impairment, indicating the need for substantial dose reduction to prevent overdose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: